Monoamine content in rat brain during carcinogenesis and the influence of the CNS drugs piracetam and imipramine.
A
A
von Metzler
C
C
Nitsch
D015102:3,4-Dihydroxyphenylacetic Acid / Q000032:analysis*; D000818:Animals; D001923:Brain Chemistry / Q000187:drug effects*; D001932:Brain Neoplasms / Q000139:chemically induced* / Q000378:metabolism; D002421:Caudate Nucleus / Q000032:analysis; D005260:Female; D006897:Hydroxyindoleacetic Acid / Q000032:analysis*; D007031:Hypothalamus / Q000032:analysis; D007099:Imipramine / Q000494:pharmacology*; D008748:Methylcholanthrene / Q000494:pharmacology; D009638:Norepinephrine / Q000032:analysis*; D010648:Phenylacetates / Q000032:analysis*; D010889:Piracetam / Q000494:pharmacology*; D011760:Pyrrolidinones / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D005680:gamma-Aminobutyric Acid / Q000032:analysis
D010648:Phenylacetates; D011760:Pyrrolidinones; D015102:3,4-Dihydroxyphenylacetic Acid; D006897:Hydroxyindoleacetic Acid; D005680:gamma-Aminobutyric Acid; D008748:Methylcholanthrene; D007099:Imipramine; D009638:Norepinephrine; D010889:Piracetam